首页> 外文期刊>Expert opinion on drug delivery >Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine
【24h】

Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine

机译:用于递送奥氮平的粘附剂透皮给药系统的开发和评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objectives: Olanzapine (OZP) is a safe and effective atypical antipsychotic drug used in treating schizophrenia and bipolar disorders. The dosage forms currently on the market for OZP are administered via oral or intramuscular routes. However, there are many problems associated with oral and intramuscular routes of drug administration. Thus, our aim was to develop a drug-in-adhesive transdermal delivery system (TDS) that can deliver OZP for 3 days. Methods: We determined passive permeation, effect of oleic acid as chemical enhancer, and delivery of OZP across different skin types. Based on preliminary studies and saturation solubility of OZP in different pressure-sensitive adhesives (PSAs), we formulated and characterized solution-based TDS in acrylate PSA and suspension-based TDS in silicone and PIB PSA, with oleic acid as chemical enhancer. Results: Acrylate solution-based TDS, silicone, and PIB suspension-based TDS delivered 58.97 +/- 6.59 mu g/sq.cm , 129.34 +/- 16.59 mu g/sq.cm, and 245.00 +/- 2.51 mu g/sq.cm, respectively, using in vitro permeation testing. PIB PSA suspension-based TDS met the 3 days desired target delivery. Skin irritation testing using In vitro EpiDerm (TM) skin irritation test (EPI-200-SIT) kit found PIB TDS to be nonirritant. Conclusion: The PIB PSA suspension-based TDS could serve as a potentially effective transdermal delivery system for olanzapine.
机译:目的:奥氮平(OZP)是一种安全有效的非典型抗精神病药物,用于治疗精神分裂症和双相情感障碍。目前市场上的OZP剂型是通过口服或肌肉注射途径给药的。然而,与口服和肌内给药途径相关的问题很多。因此,我们的目标是开发一种可以递送 OZP 3 天的粘附药物透皮给药系统 (TDS)。方法:我们测定了被动渗透、油酸作为化学增强剂的作用以及 OZP 在不同皮肤类型中的递送。基于初步研究和OZP在不同压敏胶(PSAs)中的饱和溶解度,我们以油酸为化学增强剂,配制并表征了丙烯酸酯PSA中的溶液基TDS和有机硅和PIB PSA中的悬浮基TDS。结果:使用体外渗透测试,基于丙烯酸酯溶液的 TDS、硅氧烷和 PIB 悬浮液基 TDS 分别为 58.97 +/- 6.59 μ g/sq.cm、129.34 +/- 16.59 μ g/sq.cm 和 245.00 +/- 2.51 μ g/sq.cm。基于 PIB PSA 悬浮液的 TDS 达到了 3 天的目标交付时间。使用体外表皮 (TM) 皮肤刺激试验 (EPI-200-SIT) 试剂盒进行皮肤刺激试验发现 PIB TDS 无刺激性。结论:基于PIB PSA混悬液的TDS可作为奥氮平的潜在有效透皮给药系统。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号